Tirosint Compassionate Use and Expanded Access: A Woman's Guide to Getting It Covered

What "Compassionate Use" Actually Means for an Approved Drug Like Tirosint

Compassionate use, technically called expanded access under 21 CFR Part 312 Subpart I, is an FDA mechanism designed for investigational drugs that have not yet received approval. Tirosint does not qualify for this pathway because the FDA approved the gel-cap formulation in 2012 and Tirosint-SOL (the oral solution) in 2016. Both are commercially available in the United States.

That distinction matters for you practically. Compassionate use is not the right door to knock on. The right doors are:

• IBSA's patient assistance program (PAP)
• Prior authorization appeal with your insurer
• Manufacturer copay cards (for commercially insured patients)
• GoodRx, Mark Cuban's Cost Plus Drugs, and pharmacy-specific discount programs
• HSA/FSA payment
• State pharmaceutical assistance programs (SPAPs)

Each route has different eligibility rules, and some are life-stage-specific. A woman who is pregnant, for example, has a medical urgency argument that can accelerate a prior authorization decision.

Why Women Disproportionately Need This Drug

Hypothyroidism affects women at roughly 5 to 7 times the rate it affects men, and the autoimmune form, Hashimoto's thyroiditis, is one of the most common autoimmune conditions in women of reproductive age. Approximately 5% of women develop postpartum thyroiditis, and a subset progress to permanent hypothyroidism requiring lifelong therapy. PCOS is independently associated with subclinical hypothyroidism, with some data suggesting a prevalence of hypothyroidism in 22-28% of women with PCOS compared with roughly 8% in the general female population.

Standard levothyroxine tablets are the first-line treatment and cost very little. Tirosint costs more because its gel-cap formulation eliminates most inactive ingredients (fillers, dyes, binders, and gluten), which matters when:

• You have documented absorption problems (celiac disease, bariatric surgery, H. Pylori infection, atrophic gastritis)
• You take medications that interfere with levothyroxine absorption (calcium carbonate, proton pump inhibitors, iron, cholestyramine)
• You have persistently high TSH despite correct tablet-taking technique
• You react to dye or excipient ingredients in standard tablets

Think of access to Tirosint not as a luxury request but as a clinically indicated formulation switch when standard tablets have demonstrably failed. Framing your request to your insurer and your prescriber this way changes the conversation.

IBSA Patient Assistance Program: Who Qualifies and How to Apply

IBSA Pharma operates a patient assistance program for Tirosint and Tirosint-SOL for patients who are uninsured or underinsured and meet income criteria. The program is administered directly by IBSA rather than a third-party foundation, which means the enrollment process runs through your prescriber's office.

Eligibility Criteria (Current as of Early 2026)

IBSA has not published a fixed income ceiling publicly, but most manufacturer PAPs follow a threshold of 200-400% of the federal poverty level. As of the 2025 federal poverty guidelines published by HHS, that translates to roughly $29,000-$58,000 annual income for a single adult. You will typically need:

1. A signed prescription from a licensed US prescriber
2. Proof of income (recent tax return, pay stubs, or benefits letter)
3. Proof of US residency
4. Documentation of insurance status (denial letter, insurance card showing Tirosint is excluded, or attestation of no insurance)

How to apply. Ask your prescriber or their office staff to contact IBSA Pharma directly at their medical affairs line. Many offices have a specialty pharmacy liaison who handles this. The program does not have a self-enrollment portal visible to patients; the prescriber initiates the process. If your office does not know the process, IBSA's medical affairs team can be reached through the contact information on IBSA's US prescribing information page.

Recertification

PAP enrollment is not permanent. Most programs recertify every 6-12 months. Calendar your recertification date the day you are approved. Missing it means a gap in supply.

If You Are Denied

A denial from the PAP is not final. Ask IBSA for the specific reason. Common reasons include income above threshold, active insurance (even if that insurance does not cover Tirosint), or a missing document. Each is fixable.

Prior Authorization: How to Build a Case Your Insurer Cannot Easily Dismiss

Prior authorization (PA) is the most common access barrier for Tirosint on commercial insurance and Medicare Part D. Most formularies place Tirosint on tier 3 or tier 4, or exclude it entirely, on the grounds that generic levothyroxine tablets are therapeutically equivalent for most patients.

Your job in a PA appeal is to show that tablets are not equivalent for you specifically.

The Clinical Evidence You Need

A successful PA appeal for Tirosint typically documents:

• At least one trial of generic or brand levothyroxine tablet at the correct dose and correct administration technique (taken on an empty stomach, 30-60 minutes before food, separated from interfering medications)
• Persistently elevated or variable TSH on tablets despite documented adherence, supported by lab values with dates
• A specific clinical reason for malabsorption or sensitivity: celiac disease, bariatric surgery record, H. Pylori eradication history, diagnosis of atrophic gastritis, or a medication list showing a known interacting drug that cannot be discontinued

The American Thyroid Association 2014 guidelines on hypothyroidism management, while aging, remain widely cited in PA appeal letters because they explicitly acknowledge that some patients require liquid or gel-cap formulations to achieve stable absorption. A 2013 study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that levothyroxine liquid solution normalized TSH in 77% of patients who had failed tablet therapy due to malabsorption, a figure your prescriber can cite directly in the appeal letter.

Medicare Part D Specifics

If you are a postmenopausal woman on Medicare, you face a different PA structure. Medicare Part D plans cannot exclude a drug that has no covered alternative in the same therapeutic category, but they can require PA and step therapy. The step therapy requirement for levothyroxine gel caps typically means documenting at least one failed trial on tablets. CMS guidance on step therapy allows plans to require this documentation, but your prescriber can request a step-therapy exception if tablets are contraindicated or clinically inappropriate.

Discount Programs: Real Numbers for 2026

If you are commercially insured and Tirosint is covered but expensive, or if you are paying cash, several discount programs apply.

IBSA Copay Card

IBSA offers a manufacturer copay assistance card for commercially insured patients. The card has historically reduced out-of-pocket cost to as low as $0-$30 per fill for eligible patients. Medicare and Medicaid beneficiaries cannot use manufacturer copay cards under federal rules. The card is available through your prescriber or through the Tirosint product website, and eligibility is verified at the pharmacy point of sale.

GoodRx

GoodRx pricing for Tirosint gel caps (30-count, 100 mcg) ranges from approximately $85-$140 depending on pharmacy and location as of early 2026. At certain pharmacies, GoodRx pricing approaches the cost of some branded medications. This option works whether or not you have insurance, though you cannot use GoodRx simultaneously with insurance at the same fill.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists generic levothyroxine tablets but does not currently list Tirosint gel caps or the gel-cap generic. Check the site directly, as inventory changes frequently.

Pharmacy-Specific Programs

• Amazon Pharmacy ships Tirosint nationally and publishes transparent pricing. With Prime membership, cash pricing may be lower than GoodRx at some doses.
• Costco Pharmacy does not require a membership to use the pharmacy and consistently prices brand medications below average retail.
• Mark Cuban's Cost Plus generics cover standard levothyroxine tablets at under $4 for a 90-day supply, which is worth discussing with your prescriber if the gel cap is genuinely unaffordable and tablets have not yet been trialed.

HSA and FSA: Yes, Tirosint Qualifies

Tirosint is a prescription medication treating a medical condition, which makes it a qualified medical expense under IRS Publication 502. You can pay for it with your HSA or FSA debit card at the pharmacy, or submit a receipt for reimbursement. This does not reduce the drug's price, but it does let you pay with pre-tax dollars, effectively reducing your real cost by your marginal tax rate. For a woman in the 22% federal tax bracket paying $1,200/year for Tirosint, HSA/FSA payment saves roughly $264 annually.

Pregnancy and Lactation: Access Urgency and Dose Changes You Must Know

Levothyroxine is not contraindicated in pregnancy. It is medically necessary. Uncontrolled hypothyroidism during pregnancy is associated with increased risk of miscarriage, preterm birth, low birth weight, and impaired fetal neurodevelopment. This is one situation where access delays are clinically dangerous, not merely inconvenient.

Dose Changes in Pregnancy

Levothyroxine requirements increase by approximately 30-50% beginning as early as the first 4-6 weeks of gestation, driven by increased thyroxine-binding globulin, expanded plasma volume, and placental transfer of T4. The Endocrine Society's 2012 clinical practice guideline on thyroid disease in pregnancy recommends checking TSH as soon as pregnancy is confirmed and at weeks 4, 8, 12, 16, 20, 24, and 28 if the woman has known hypothyroidism. Some practitioners advise women who are actively trying to conceive to have a "pregnancy dose" instruction ready in advance.

If you are taking Tirosint because tablets failed you due to absorption issues, stopping Tirosint in pregnancy to save money is not a safe trade-off. The access urgency argument is real. When filing a PA appeal during pregnancy, include gestational age and the specific risks of undertreated hypothyroidism in the letter. Many insurers expedite PA decisions for pregnant members under internal medical necessity policies, and ACOG has documented the maternal and fetal risks of hypothyroidism that support this urgency.

Trying to Conceive (TTC)

If you are trying to conceive, TSH should be maintained below 2.5 mIU/L, according to the Endocrine Society guideline. If your TSH is elevated or unstable on tablets, that instability directly affects your fertility. Access to the formulation that achieves a stable TSH is a fertility issue, not a preference issue. Frame it that way with your insurer.

Lactation

Levothyroxine transfers into breast milk in small amounts. This is not a safety concern. Thyroid hormone is present in breast milk physiologically, and exogenous levothyroxine at replacement doses does not meaningfully increase the infant's hormone exposure. The LactMed database at NIH classifies levothyroxine as compatible with breastfeeding. No dose adjustment is needed for lactation, though your own dose may decrease back toward your pre-pregnancy level in the weeks after delivery. TSH should be checked at 6 weeks postpartum.

Postpartum Thyroiditis

If you developed postpartum thyroiditis and are now in the hypothyroid phase requiring treatment, you may be newly starting levothyroxine. Starting directly on Tirosint is clinically reasonable if you have a documented reason (celiac, bariatric history, interacting medication). However, most postpartum thyroiditis-related hypothyroidism is transient; roughly 80% of women recover thyroid function within 12 months. Your prescriber may start tablets first given the likelihood of discontinuation, which is worth a frank conversation about cost versus the temporary nature of the indication.

Life-Stage Guide: Who Should Prioritize Access to Tirosint Over Generic Tablets

Not every woman needs Tirosint. Here is an honest breakdown by life stage.

Reproductive Years (Ages 18-40)

You are the group most likely to benefit from Tirosint if you have PCOS with hypothyroidism, celiac disease, inflammatory bowel disease, or are taking oral contraceptives. Estrogen-containing contraceptives increase thyroxine-binding globulin, which can alter free T4 levels and change your dose requirement. This does not by itself make Tirosint necessary, but it does mean your TSH should be rechecked 6-12 weeks after starting or stopping hormonal contraception.

Perimenopause (Typically Ages 45-55)

Hormonal flux in perimenopause can destabilize previously well-controlled thyroid disease. TSH targets may need adjustment, and absorption variability becomes more clinically relevant. Women in perimenopause who are also starting or adjusting hormone therapy (HT) for menopause symptoms should recheck TSH 6-8 weeks after any HT change, because estrogen-containing HT increases thyroxine-binding globulin just as oral contraceptives do. The Menopause Society (NAMS) recommends monitoring thyroid function when initiating or changing HT, particularly in women with known thyroid disease.

Postmenopause

Postmenopausal women are at higher risk for both hypothyroidism and osteoporosis. Excess levothyroxine in this group is associated with bone loss and increased fracture risk, while under-replacement carries its own risks. Dose precision matters more, which is one argument for a formulation with more predictable absorption. Access through Medicare Part D (as described above) is the relevant route for this group.

What to Do If Every Access Route Fails

If the PAP, PA appeal, copay card, and discount programs all result in a cost you cannot manage, have this conversation openly with your prescriber:

1. Can we trial generic levothyroxine tablets one more time with rigorous technique (consistent brand, strict 30-minute fasting, separation from all interacting medications) to see if TSH stabilizes?
2. If yes, what TSH threshold or timeline signals that we need to return to Tirosint?
3. If tablets genuinely cannot control my TSH, does my state have a pharmaceutical assistance program that covers specialty-formulary thyroid medications?

State pharmaceutical assistance programs vary widely. Medicare's Extra Help program (Low Income Subsidy) can also reduce Part D cost-sharing for eligible postmenopausal women on Medicare.

The worst outcome is rationing or skipping doses because cost is unmanageable. Undertreated hypothyroidism affects cardiovascular function, fertility, bone turnover, mood, and cognitive function. No access barrier is worth accepting an untreated TSH.

Frequently Asked Questions